UGT2B17 and metastatic neoplasm: (4) We established the UGT2B17 transcriptome in the prostate and tumours to corroborate our observations at the protein level, and (5) identified alternative promoters as a mechanism governing UGT2B17 expression in the prostate, localised PCa and metastatic disease.